ARCH Arch Biopartners Inc.
0.8300CAD0.00%Mkt Cap: 41.06M $P/E: —3d ago
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.24BUSDP/E 36.1
$44.29BUSD
$41.63BUSDP/E 17.7
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.61BUSDP/E 29.3
$21.69BUSDP/E 27.4
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Arch Biopartners to Expand Ongoing Phase 2 LSAT Peptide Trial to The US Arch Biopartners (ARCH.V) will expand its Phase II trial of LSALT peptide into the US, with five ins | ||